Autolus (AUTL) director Martin Anton Pule reports options, RSUs and ADS
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Autolus Therapeutics plc director Martin Anton Pule filed an initial insider ownership report listing his existing equity interests in the company. The filing shows multiple share option awards over American Depositary Shares with exercise prices from $0.001 to $30.29 and expiration dates extending through 2036.
He also reports 50,000 restricted share units that vest in four equal annual installments starting on January 26, 2027, with each unit convertible into one American Depositary Share. In addition, he holds 70,000 American Depositary Shares directly. The filing records holdings only and does not reflect new market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Pule Martin Anton
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 34,306 shares (Direct);
Restricted Share Units — 50,000 shares (Direct);
American Depositary Shares — 70,000 shares (Direct)
Footnotes (1)
- Fully vested and exercisable. This option vested 25% on July 22, 2023 and the remainder vests in 36 equal monthly installments thereafter. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
FAQ
What does the Autolus Therapeutics (AUTL) Form 3 filing disclose?
The Form 3 discloses director Martin Anton Pule’s existing equity holdings in Autolus Therapeutics. It lists multiple option grants, 50,000 restricted share units, and 70,000 American Depositary Shares, providing a baseline of his ownership at the time of becoming a reporting insider.
What stock options does Martin Anton Pule hold in Autolus (AUTL)?
He holds several option awards over American Depositary Shares with exercise prices ranging from $0.001 to $30.29 and expirations running from 2027 through 2036. Each award covers a specific number of underlying shares, reflecting long-term, equity-based compensation grants.